WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will host a conference call and webcast Friday, September 27, 2019, at 11:00 a.m. EDT (5:00 p.m. CEST), to discuss updated pemigatinib data presented at the European Society for Medical Oncology (ESMO) 2019 Congress as well as potential future development opportunities for the product candidate.
Conference call information:
- Date and Time: September 27, 2019, 11:00 a.m. EDT (5:00 p.m. CEST)
- Domestic Dial-In Number: 877-407-3042
- International Dial-In Number: +1 201-389-0864
- Conference ID Number: 13694537
The live webcast and slides can be accessed via the Events and Presentations tab of the Investor section of www.incyte.com and will be available for replay for 30 days.
If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415. To access the replay you will need the conference ID number 13694537.
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company’s website at www.incyte.com.
Follow @Incyte on Twitter at https://twitter.com/Incyte.